It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice

Michael C Gundry; Margaret A Goodell; Lorenzo Brunetti

doi:10.1016/j.ccell.2020.02.011

It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice

Cancer Cell. 2020 Mar 16;37(3):267-269. doi: 10.1016/j.ccell.2020.02.011.

Authors

Michael C Gundry¹, Margaret A Goodell², Lorenzo Brunetti³

Affiliations

¹ Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
² Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA; Stem Cell and Regenerative Medicine, Baylor College of Medicine, Houston, TX, USA.
³ Department of Medicine, University of Perugia, Perugia, Italy. Electronic address: lorenzo.brunetti@unipg.it.

PMID: 32183947
DOI: 10.1016/j.ccell.2020.02.011

Abstract

Several acute myeloid leukemia genetic sub-types converge on high expression of HOX genes, critical for their self-renewal. A new orally bioavailable Menin-MLL inhibitor (VTP-50469) appears to promote their differentiation through direct effects on the HOX cofactor MEIS1, paving the way for clinical trials.

Publication types

Comment

MeSH terms

Animals
Chromatin
Histone-Lysine N-Methyltransferase / genetics
Homeodomain Proteins / genetics*
Mice
Myeloid-Lymphoid Leukemia Protein / genetics*
Nuclear Proteins
Nucleophosmin

Substances

Chromatin
Homeodomain Proteins
NPM1 protein, human
Npm1 protein, mouse
Nuclear Proteins
Nucleophosmin
Myeloid-Lymphoid Leukemia Protein
Histone-Lysine N-Methyltransferase